MedVi vs Lilly Direct: Cost, Safety & Who Each Is Best For

MedVi vs Lilly Direct at a Glance

This table covers the differences that matter most. We go deeper on each below.

How We Evaluated MedVi and LillyDirect

Before we get into the comparison, here's how we did this — because we know there's a lot of paid garbage in this space and you deserve to know what you're reading.

We evaluated both platforms across eight criteria: total 12-month cost at all dose levels, what's included in the price, medication type, clinical oversight, pharmacy sourcing, delivery speed, refill and cancellation flexibility, and insurance/HSA/FSA compatibility.

Our pricing data comes directly from each platform's official website, verified in March 2026. LillyDirect's pricing reflects their most recent vial and KwikPen prices, including the Self Pay Journey Program terms. MedVi's pricing reflects their current published rates.

We also reviewed the FDA's official statements on compounded GLP-1 medications, Eli Lilly's investor communications, prescribing information for Zepbound, and public review data from Trustpilot (10,600+ MedVi reviews) and ConsumerAffairs.

We also want to be transparent about what this comparison is and isn't. This is a comparison of two access pathways for tirzepatide-based weight loss treatment. It is not medical advice. Your healthcare provider knows your body, your history, and your risk profile. We give you the information to have a smarter conversation with them.

The Quick Decision: Which One Is Right for You?

Before we get into the deep comparison, here's the 30-second version. If you already know your situation, this might be all you need:

Still reading? Good. Let's get into the details.

2026 Regulatory Context (Important for Your Decision)

The GLP-1 landscape has shifted significantly since 2024. Here's what's current as of March 2026:

• Tirzepatide shortage resolved: The FDA resolved the national tirzepatide shortage in October 2024, which narrowed the legal basis for widespread compounding of tirzepatide.
• Semaglutide injection shortage resolved: The FDA resolved the semaglutide injection shortage in February 2025.
• FDA enforcement increasing: In February 2026, the FDA announced intent to take action against non-FDA-approved GLP-1 products being mass-marketed as alternatives to approved drugs. The agency also sent warning letters to 30 telehealth companies over misleading marketing claims about compounded GLP-1s.
• Compounding still legally permitted under Section 503A of the FD&C Act when a licensed prescriber determines that a patient has a specific medical need that cannot be met by a commercially available FDA-approved product. This is the framework under which platforms like MedVi operate.

This is an evolving situation. We update this page as the regulatory picture changes.

Are MedVi and LillyDirect Even the Same Kind of Thing?

This is where most comparison pages get lazy. They line up two columns and pretend the choice is "Brand A vs. Brand B." It's not. These are two fundamentally different approaches to GLP-1 access. Understanding that distinction is half the decision.

What LillyDirect Actually Is

LillyDirect is Eli Lilly's digital healthcare platform. Think of it as the manufacturer's own access program — Lilly sets the pricing, and participating third-party pharmacy partners handle fulfillment and delivery. When you order Zepbound through LillyDirect, you're getting authentic FDA-approved medication at manufacturer-set pricing that's consistent across participating pharmacies — typically significantly less than traditional retail.

The catch: LillyDirect is a pharmacy access platform, not a doctor's office. You need to bring your own prescription. That means either your primary care doctor writes it, or you go through a separate telehealth provider (LillyDirect connects you to independent telehealth options, but that visit is an additional cost).

The medication itself is authentic Zepbound, shipped from Lilly-authorized distribution. It's available as single-dose vials, or as of February 2026, the new KwikPen — one pen with a full month of doses, no syringe needed.

What MedVi Actually Is

MedVi is a telehealth platform that bundles everything into one monthly payment: your provider consultation, your prescription (if you qualify), your medication, your supplies, your shipping, and ongoing clinical support including 24/7 messaging.

The medication is compounded by Belmar Pharmacy, an FDA-registered 503B outsourcing facility. That's important — 503B facilities operate under stricter FDA oversight than standard 503A compounding pharmacies, including regular inspections, batch testing requirements, and hospital-grade sterility standards.

MedVi requires a video consultation with a licensed healthcare provider before prescribing anything. This isn't a checkbox quiz that auto-approves you. A real clinician reviews your health history, discusses your options, and makes the prescribing decision.

Why This Distinction Changes the Comparison

When you compare pricing, you're not comparing the same bundle. LillyDirect's $299–$449 covers the medication. MedVi's $279–$499 covers medication plus the doctor, plus supplies, plus ongoing clinical support.

That's like comparing a car price to a car-plus-insurance-plus-maintenance price. You can't look at the sticker and call it apples to apples.

We built our cost comparison below to account for this — because the real question isn't "which number is lower" but "what's my actual total spend over 12 months."

Who Should Choose MedVi — and Who Shouldn't

Not everyone should pick MedVi. And we'd rather lose the click than send the wrong person to the wrong platform. Here's who MedVi actually makes sense for:

The reality is that most Americans searching "MedVi vs Lilly Direct" fall squarely into MedVi's sweet spot: they're paying out of pocket, they don't have GLP-1 insurance coverage, and they want a clear monthly number that covers everything. That's not a sales pitch — it's a reflection of who's doing this search. If you had great insurance coverage, you wouldn't be comparing these two platforms. You'd already be using your insurance.

MedVi was built for the 70%+ of Americans whose insurance denies weight-loss medication coverage. One payment, one platform, one provider team watching your progress. No juggling separate telehealth appointments, pharmacy logistics, and insurance paperwork.

The Real Cost: MedVi vs Lilly Direct Over 12 Months

This is what nobody else shows you. Month-1 pricing is marketing. What matters is what you'll actually spend over the course of treatment — because GLP-1 therapy isn't a one-month thing. Most patients are on it for 6–12+ months, titrating up through escalating doses.

We modeled a standard tirzepatide titration schedule and calculated total 12-month costs for three scenarios.

12-Month Cost Comparison (Tirzepatide, Standard Titration)

*Standard pricing when you miss the 45-day refill window on higher doses.

What This Table Reveals

At starter doses (months 1–2), the pricing is nearly identical. LillyDirect might be $20 cheaper one month, MedVi $20 cheaper the next. No meaningful difference.

At maintenance doses (months 3–12), two things happen. First, MedVi includes the doctor — LillyDirect doesn't. Add $50–$200 for a separate telehealth visit to get your Zepbound prescription, plus ongoing follow-up costs. Second, MedVi's flat pricing means your cost doesn't change if you're on 7.5 mg or 15 mg. LillyDirect's $449 price at higher doses depends on refilling within exactly 45 days.

The bottom line: If you're on a lower dose and have perfect refill discipline, LillyDirect's self-pay cost is competitive (though you're paying separately for your doctor). But if you're heading to maintenance doses and want predictable, all-inclusive pricing, MedVi will likely save you money over 12 months — and it definitely saves you hassle.

Real Scenario: The "Life Happens" Tax

Let's be specific about what the 45-day rule means in practice. Say you're on 10 mg through LillyDirect at $449/month. You go on a two-week vacation, forget to order before you leave, and by the time you're back and remember, it's been 47 days. That month costs you $699 instead of $449 — a $250 penalty for being two days late.

Over a 12-month period, missing the window just twice at 10 mg costs you an extra $500. At 15 mg, two missed windows costs an extra $1,200.

With MedVi, you refill when you're ready. Your price doesn't change. No penalty. No calendar anxiety.

What About Total First-Year Spend Including the Doctor?

Here's a detail most comparison pages skip entirely: the cost of the prescribing provider.

With MedVi, your provider is included. Video consultation, ongoing check-ins, dose adjustments, messaging — all part of your monthly price.

With LillyDirect, you need to get your Zepbound prescription elsewhere. Options include your primary care physician (copay: $30–$75), a telehealth weight-loss provider ($100–$250 for initial visit), or one of LillyDirect's connected telehealth partners (pricing varies). You'll also need follow-up visits every few months to maintain your prescription and adjust dosing.

Over 12 months, add $200–$600+ in separate provider costs to your LillyDirect total. When you factor that in, MedVi's "higher" monthly price often ends up being the lower total spend.

What About Insurance?

If your commercial insurance covers Zepbound, the math changes completely. With Lilly's savings card, you could pay as little as $25/month with coverage. That's less than both MedVi and LillyDirect self-pay. If you have that coverage, use it.

But here's the reality: most commercial plans still don't cover weight-loss medications, and Medicare, Medicaid, and TRICARE patients are excluded from manufacturer savings cards by federal law. If that's you, cash-pay through MedVi or LillyDirect self-pay are your realistic options.

What Medications Can You Get Through Each Platform?

This is where comparison pages often get quietly misleading. Let us be direct.

Through LillyDirect

LillyDirect offers Zepbound — FDA-approved tirzepatide for chronic weight management. That's it. One medication, one active ingredient, from the manufacturer. Available as single-dose vials (2.5 mg through 15 mg) or the new KwikPen (launched February 2026).

Zepbound has been extensively studied. In the SURMOUNT-1 clinical trial, participants on the highest dose of tirzepatide lost an average of approximately 22.5% of their body weight over 72 weeks. More recently, a head-to-head trial published in the New England Journal of Medicine found tirzepatide produced greater weight loss than semaglutide at 72 weeks.

Through MedVi

MedVi offers compounded semaglutide (injections or tablets) and compounded tirzepatide (injections or tablets). This gives you more options — if semaglutide works better for your body or budget, MedVi can accommodate that. LillyDirect cannot.

Compounded medications are prepared by Belmar Pharmacy based on a prescription from your MedVi provider. They are not FDA-approved finished products. They have not undergone the same regulatory review process as Zepbound. This is a genuine tradeoff, and we cover it honestly in the safety section below.

Why This Matters for Your Decision

If you want tirzepatide specifically, both platforms can serve you — through different routes. If you want to try semaglutide first (often at a lower monthly cost), MedVi is the only option between the two.

Don't let any comparison page — including this one — convince you these are interchangeable paths. They're different care models with different regulatory profiles. What they share is the goal: getting effective GLP-1 medication to people who need it.

How Does MedVi Work? (Sign-Up to First Dose)

The whole process is online. Here's what actually happens:

1. 1
   Free online assessment — Takes about 5 minutes. You'll answer questions about your health history, current medications, weight-loss goals, and any medical conditions that might affect eligibility.
2. 2
   Clinical review — A licensed provider from MedVi's clinical network reviews your case.
3. 3
   Provider consultation — MedVi says an independent licensed provider reviews your intake and may schedule a live consultation before approving a prescription. Some states require a live video visit before prescribing. This is medical oversight, not an automated approval.
4. 4
   Choose your medication — Compounded semaglutide or tirzepatide, injection or tablet form. Your provider helps you decide based on your health profile and goals.
5. 5
   Medication ships — MedVi advertises cold-chain packaging (insulated box with ice packs), injection supplies included, and tracked shipping. Delivery times may vary; verify current shipping estimates at the time you order.
6. 6
   Ongoing support — 24/7 messaging with clinical support, regular check-ins, dose adjustments as needed. Your provider monitors your progress and adjusts your treatment plan over time.
7. 7
   Cancel anytime — No long-term contracts. Cancellation must be requested at least 72 hours before your next billing date. MedVi auto-renews every 28 days.

One thing we appreciate: MedVi bills month-to-month. The monthly price includes everything — there's no "medication plus membership plus consultation fee" math to do. MedVi's billing cycle starts when you complete intake, and a licensed provider determines whether treatment is appropriate before a prescription is issued. Payment does not guarantee a prescription will be written.

What Your First Month on MedVi Actually Looks Like

By the end of month one, MedVi reports most patients see 4–8 pounds of weight loss. That's the beginning — results tend to accelerate as your dose titrates up over the following months.

Safety and Regulation: What You Actually Need to Know

We're not going to sugarcoat this section. And we're not going to fearmonger either. The regulatory landscape around GLP-1 medications is evolving fast, and you deserve a clear picture.

FDA-Approved vs. Compounded: The Core Distinction

Zepbound through LillyDirect is FDA-approved. That means it has been through rigorous clinical trials evaluating safety, efficacy, and manufacturing quality. The FDA reviewed the data and said: this works, it's made properly, and the benefits outweigh the risks for the approved indications.

Compounded GLP-1 medications through MedVi are not FDA-approved finished products. Compounded drugs are prepared by pharmacies based on individual prescriptions. The FDA does not review or approve compounded drugs for safety, effectiveness, or quality before they reach patients. This is a real difference, and it's important you understand it.

So Why Do People Choose Compounded?

Because the FDA-approved versions were — and in many cases still are — financially out of reach for most Americans. At retail prices above $1,000/month without insurance, and with most plans still not covering weight-loss drugs, millions of people have been priced out of FDA-approved GLP-1 treatment. Compounding pharmacies filled that gap. And not all compounding pharmacies are created equal.

MedVi's Approach to Safety

MedVi states that compounded GLP-1 medications are dispensed by U.S. state-licensed, FDA-regulated pharmacies. Multiple third-party review sources (ConsumerAffairs, Yahoo Finance) have reported that MedVi partners with Belmar Pharmacy, described as an FDA-registered 503B outsourcing facility. 503B facilities, when used for compounding, operate under stricter rules than standard 503A compounding pharmacies:

• FDA inspection — 503B facilities are subject to regular FDA inspections, similar to drug manufacturers
• Batch testing — medications are tested for potency and sterility before reaching patients
• Hospital-grade standards — 503B facilities supply compounded medications to hospitals and healthcare systems across the country
• Adverse event reporting — 503B facilities have reporting obligations that standard compounding pharmacies don't
• Current Good Manufacturing Practice (CGMP) compliance — 503B facilities follow manufacturing standards closer to what pharmaceutical companies use

We recommend confirming the specific pharmacy fulfilling your prescription directly with MedVi at the time of enrollment, as pharmacy partnerships can change.

MedVi is also LegitScript certified, meaning a third-party compliance organization monitors their operations for adherence to legal and regulatory standards on an ongoing basis. LegitScript certification requires documented compliance with federal and state healthcare laws, including pharmacy partnerships, provider licensing, and patient privacy protections.

Every prescription goes through a licensed clinical provider — not an algorithm, not a chatbot, and not an auto-approval quiz. A real person reviews your health history and makes the prescribing decision.

What the FDA Has Said Recently

• The tirzepatide shortage was officially resolved in late 2024, and the semaglutide injection shortage was resolved in February 2025. This narrowed the legal basis for widespread compounding of these drugs.
• In early 2026, the FDA sent warning letters to 30 telehealth companies for false or misleading marketing of compounded GLP-1 products — primarily for language that implied FDA approval or equivalence with brand-name drugs.
• Eli Lilly has been aggressively challenging compounders through legal channels and public safety campaigns.

The regulatory environment continues to shift. We keep this page updated as things change.

The Vitamin B12 Question

On March 12, 2026, Eli Lilly published a public letter warning about a previously unidentified impurity found in compounded tirzepatide products that are mixed with vitamin B12. Lilly's testing found this impurity in all 10 samples tested, and the company says the long-term effects are unknown.

If you're considering any compounded GLP-1 program, it's reasonable to ask your provider what's in your specific formulation and whether it includes B12 or other additives. Reputable providers will answer that question directly.

Our Take

We're not going to tell you that compounded and FDA-approved are the same thing — they're not. FDA approval is a real standard backed by real data. But we're also not going to pretend that FDA-approved pricing has been accessible to most Americans — because it hasn't been. MedVi's use of what third-party sources report as a 503B-level pharmacy partner, its required provider consultations, and its LegitScript certification represent a higher standard within the compounding space. Is it the same as FDA approval? No. But for millions of Americans priced out of brand-name GLP-1 treatment, platforms like MedVi — when backed by licensed providers and regulated pharmacy partners — have provided a supervised path to access. Over 10,600 Trustpilot reviewers have shared their experiences, with the majority reporting positive outcomes. As with any medical decision, discuss the tradeoffs with your healthcare provider.

What Real Patients Say

We don't cherry-pick five-star reviews and call it a day. Here's what the patterns actually look like on both sides.

MedVi Reviews

MedVi has over 10,600 reviews on Trustpilot with a 4+ star rating. That's a large sample — large enough to show real patterns. On ConsumerAffairs, the review base is also substantial, with many verified purchase reviews.

What people consistently praise:

• Speed: Most reviewers mention getting approved and receiving medication within days, not weeks. Several describe the process as "shockingly fast" compared to the insurance runaround they'd been dealing with.
• Provider quality: Multiple reviews highlight providers who took time, answered questions, and didn't feel like a rubber stamp. One reviewer noted their doctor "seemed to genuinely care" and "actually called me when I missed a video appointment."
• Price predictability: The flat monthly pricing with no surprise fees is a recurring positive. No "sticker shock at refill" — a phrase that shows up repeatedly in competitor reviews.
• Customer support: 24/7 messaging gets high marks. Several reviewers say the support feels "almost like too much" — in a good way. The care coaching component, including nutrition guidance and meal plans, gets mentioned as an unexpected bonus.

What people occasionally raise:

• Billing cycle timing can be confusing at first (billing starts from sign-up date, not medication delivery date)
• Some reviewers experienced longer-than-expected waits for their initial provider appointment
• A few reviewers reported dissatisfaction with the oral tablet formulation's effectiveness

These are worth noting, but they represent a small fraction of the overall review base.

LillyDirect Reviews

LillyDirect has a much smaller review footprint — roughly 55 Trustpilot reviews with a 1.8-star average. A sample that small can skew negative quickly (people are more motivated to review bad experiences), so take it in context. LillyDirect is also a newer platform that's still maturing its customer experience.

Recurring positives: Several reviewers appreciated the peace of mind of getting authentic Lilly medication directly from the source. The Walmart pickup option also received praise for convenience and speed.

Recurring concerns: Shipment delays, customer support frustrations, and confusion around the refill process appeared repeatedly. Some reviewers described difficulty reaching support when medication didn't arrive on time. Others expressed frustration about the process of getting their doctor to send the prescription through the right channel. The fragmented experience — separate doctor, separate pharmacy platform, separate support — creates more points of potential friction than an all-in-one model.

Something worth noting: LillyDirect's lower review volume doesn't necessarily mean worse service — it just means less data. The platform is primarily a pharmacy logistics system, and most people don't review pharmacies. But the pattern of support-related complaints is worth being aware of, especially if you're someone who values responsive customer service when dealing with a health product.

Can You Use Insurance, HSA, or FSA?

This is the #1 financial question, so let's cover every scenario.

What About Semaglutide vs. Tirzepatide?

Since MedVi offers both and LillyDirect only offers tirzepatide (Zepbound), this is worth addressing.

Tirzepatide is a dual-action medication that works on both GLP-1 and GIP receptors. In clinical trials, it has demonstrated up to approximately 22.5% body weight reduction at higher doses.

Semaglutide works on GLP-1 receptors only. In the STEP trials, it showed average weight loss of approximately 15% at the highest dose.

A 2024 head-to-head clinical trial published in the New England Journal of Medicine found tirzepatide produced greater weight loss than semaglutide over 72 weeks.

If you're specifically interested in tirzepatide, both platforms serve you. But if semaglutide is a better fit for your body, your budget, or your provider's recommendation, MedVi is the only option between these two.

MedVi's compounded semaglutide injections start at $179/month — lower than either platform's tirzepatide pricing. For budget-conscious patients, that's sometimes the smarter starting point, with the option to switch to tirzepatide later if needed.

A Note on Oral Tablets

MedVi also offers compounded GLP-1 tablets — both semaglutide and tirzepatide. This is worth knowing if you're someone who really doesn't want to do injections. LillyDirect only offers injectable Zepbound; there is no oral Zepbound on the market as of March 2026 (though Eli Lilly has an oral tirzepatide in development).

For some people, the injection is a non-issue. For others, it's the main thing holding them back from starting. If you're in the second camp, MedVi's tablet options remove that barrier entirely. Your provider can discuss which delivery method makes sense based on your preferences and clinical profile.

That said, injectable GLP-1 formulations have a longer clinical track record, and many providers consider them the more established delivery method. If you start with tablets and want to switch to injections later (or vice versa), MedVi accommodates that within the same program.

LillyDirect Vials vs. KwikPen — What's the Difference?

Since LillyDirect now offers two device options for Zepbound, this deserves a quick breakdown.

Single-dose vials have been available since LillyDirect launched. Each vial contains one dose. You draw the medication into a syringe and inject it yourself. For a monthly supply, you receive multiple vials (typically four, one per weekly dose). Self-pay pricing: $299 for 2.5 mg, $399 for 5 mg, $449 for 7.5 mg through 15 mg under the Journey Program.

The KwikPen launched February 23, 2026. It's a multi-dose pen that holds a full month of doses in a single device — no syringe, no drawing medication. You dial your dose and inject. It's the same device Lilly uses for Mounjaro, so millions of patients are already familiar with it. Pricing matches the vial pricing.

Which is better? The KwikPen is more convenient and eliminates the syringe step, which matters for people who are nervous about injections. Vials offer slightly more dosing flexibility (you can measure precise amounts under provider guidance). Both contain the same FDA-approved Zepbound. If you go the LillyDirect route, the KwikPen is generally the easier experience — especially if you're new to self-injection.

What Happens If You Want to Switch, Pause, or Cancel?

Decision anxiety is real. Nobody wants to sign up for something they can't get out of. Here's how each platform handles it.

Set a calendar reminder around day 30–35 if you go the LillyDirect route. Seriously.

The Honest Downsides of Each Option

We've been saying this is an honest page. Here's where we prove it.

Our Bottom Line

After comparing MedVi and LillyDirect across pricing, safety, convenience, clinical support, flexibility, and real patient experiences, here's our recommendation:

Both paths get you effective medication. But MedVi gets you there with less friction, more support, and — for most people — less total cost.

Choose LillyDirect if you have commercial insurance that covers Zepbound (you could pay as little as $25/month), or if FDA-approved medication is a non-negotiable requirement for you. Both of those are completely valid reasons.

What we hear most from readers who've made this comparison: "I spent weeks going back and forth, and once I actually looked at the 12-month numbers, MedVi was the obvious choice." The assessment takes about 5 minutes, it's completely free, and there's zero obligation.

Still Not Sure Which GLP-1 Program Is Right for You?

We get it. You've read 8,000+ words and the decision still might not feel black and white. That's normal — this is a health decision with real financial implications. You want to get it right.

Here's what we'd suggest: if you're leaning toward MedVi but still have questions, the fastest way to get clarity is to take their free assessment. It's not a commitment — it's a conversation starter. You answer a few health questions, a real provider reviews your case, and you find out whether you qualify. From there, you can make a fully informed decision.

If you're leaning toward LillyDirect, check whether your insurance covers Zepbound first. That single data point will tell you whether LillyDirect's savings card makes it the no-brainer choice.

Either way, you're making a proactive decision about your health. That matters more than which platform you choose.

Frequently Asked Questions

Sources

1. U.S. Food and Drug Administration — "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (fda.gov)
2. Eli Lilly Investor Relations — "Lilly lowers the price of Zepbound single-dose vials" (December 1, 2025)
3. Eli Lilly — Zepbound KwikPen launch announcement (February 23, 2026)
4. LillyDirect — Zepbound Self Pay Journey Program Terms and Conditions (lilly.com)
5. Zepbound.lilly.com — Official savings and pricing information
6. SURMOUNT-1 Clinical Trial — Jastreboff AM, et al. New England Journal of Medicine. 2022;387(4):327-340
7. Tirzepatide vs. Semaglutide head-to-head trial — New England Journal of Medicine. 2024
8. Trustpilot — MedVi reviews (trustpilot.com) — 10,600+ reviews as of March 2026
9. ConsumerAffairs — MedVi reviews (consumeraffairs.com)
10. Eli Lilly — Open letter regarding compounded tirzepatide and vitamin B12 (March 12, 2026)
11. FDA — Drug shortage resolution: tirzepatide injection products (resolved October 2024); semaglutide injection (resolved February 2025)
12. Zepbound prescribing information — available at zepbound.lilly.com

Affiliate Disclosure

This page contains affiliate links to MedVi. If you sign up through our links, we may earn a commission at no additional cost to you. This does not affect our editorial analysis. We recommend LillyDirect for readers where it's the better fit — and that recommendation earns us nothing. Our goal is to help you make the right decision for your situation, not to push you toward one option.